Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Files Gene Panel Test for Use as Companion Diagnostic to Entrectinib
January 21, 2019
- Novo to Cease Dealings with 6 Wholesalers from April to Cut Distribution Costs
January 21, 2019
- Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment
January 18, 2019
- Ethical Drug Sales Slip 0.2% in November: Crecon
January 18, 2019
- Astellas, AstraZeneca Wind Up Symbicort Collaboration
January 18, 2019
- Takeda Becomes 1st Japan Drug Maker to Ring Opening Bell at NYSE
January 16, 2019
- Daiichi Sankyo Launches PIII DS-8201 Study in HER2-Low Breast Cancer
January 16, 2019
- Beverage Maker DyDo to Enter Orphan Drug Field Aiming at “Second Pillar of Business”
January 16, 2019
- Insomnia Treatment Lemborexant Filed for US Approval: Eisai, Purdue Pharma
January 16, 2019
- Fujifilm to Introduce Automatic Aseptic Filling System in US Bio CDMO Hub
January 16, 2019
- Mitsubishi Tanabe Stepping Up Rupafin Promotion in November: Anterio
January 15, 2019
- Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise
January 15, 2019
- Avastin Top-Seller Medicine in Japan in December: Encise Snapshot
January 11, 2019
- Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September
January 11, 2019
- Wakamoto Kicks Off Japan PIII for Glaucoma Drug
January 11, 2019
- Fujifilm’s Next-Generation Technology Doubles Antibody Productivity, Reduces Production Time by 30%
January 11, 2019
- NanoCarrier Submits CTA in EU for PII Study of NC-6004-Keytruda Combo for Head and Neck Cancer
January 11, 2019
- Daiichi Sankyo, Tokyo Institute of Technology Launch Open Innovation Research for Type 1 Diabetes Treatment Using iPS Cells
January 11, 2019
- Opdivo Extends OS in Second-Line Esophageal Cancer
January 10, 2019
- Chugai Completes Transfer of 13 Off-Patent Brands to Taiyo
January 10, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…